Session Abstract – PMWC 2020 Silicon Valley


Applications of precision medicine require the integration of various data that is accessible and searchable by stakeholders such as the physician and patient. This requires optimized integration and indexing of disparate data sources – germline and tumor DNA sequence, RNA-seq, pathology, clinical, ePRO, and population data – in a cloud-based system that supports artificial intelligence demands. This session will discuss how the Indiana University School of Medicine is applying LifeOmic’s software for its Precision Health Initiative to accelerate research and deliver precision treatment.

 Session Chair Profile

M.D., Founder & CEO, LifeOmic

Biography
Dr. Don Brown is the most successful serial software entrepreneur in the Midwest. His first company was acquired by EDS in 1986. He founded Software Artistry in 1988 which became the first software company in Indiana ever to go public and was later acquired by IBM for $200 million. Don then founded and served as CEO of Interactive Intelligence which went public in 1999 and was acquired by Genesys Telecommunications Laboratories in 2016 for $1.4 billion. Don received a bachelor’s in physics from Indiana University in 1978, a master’s in computer science from IU in 1982, an MD from the Indiana University School of Medicine in 1985, and a master’s in biotechnology from Johns Hopkins University in 2017.


 Speaker Profile

Ph.D., Associate Professor of Surgery, Indiana University School of Medicine

Biography
Dr. Milan Radovich is also Vice President for Oncology Genomics at Indiana University Health and co-leads the IU Health Precision Genomics Program, a clinical program dedicated to the integration of cutting-edge genomics for the care of metastatic cancer patients. As an NCI-funded investigator, his research expertise focuses on the use of genomics in translational oncology. In particular, his research concentrates on the use of genomics for precision medicine, clinical trials, genomically-informed drug combinations, circulating biomarkers of cancer detection, companion diagnostics, and novel bioinformatic pipelines for cancer genome analyses. His lab has long standing-expertise in the research of triple-negative breast cancer, thymic malignancies, and cancer precision medicine. As co-director of the IU Health Precision Genomics Program, he helps lead a clinical service line that uses cancer genomics and germline pharmacogenomics to guide therapy for cancer patients. This program has sequenced over 2000 patients to date. With four clinics across the state of Indiana, the program provides access to cutting-edge genomic-based cancer care for patients. Dr. Radovich is passionate about providing the best care to patients through precision medicine.